A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market.
However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. Despite this low valuation, the company has outperformed the S&P 500 on both dividend income and capital appreciation.
Furthermore, this low valuation also supports an opportunity for outsized future gains at below-average levels of risk. In addition to the company’s extremely high quality, the significant undervaluation provides a margin of safety as an additional layer of risk mitigation.
In this video, I will be running Bristol Myers Squibb by the numbers via the FAST Graphs fundamentals analyzer software tool. In addition to providing a fundamental analysis of the company, I will simultaneously be illustrating the power of the FAST Graphs research tool as well as how to use it to your maximum benefit.
FAST Graphs Analyze Out Loud Video
— Chuck Carnevale
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years. But the Man Who Called Nvidia at $1.10 Says "AI's Next Magnificent Seven Could Do It Even Faster." See His Breakdown of the Seven Stocks You Should Own Here.
Source: FAST Graphs
